On May 20, 2020 Predictmedix (PMED.C) cut a deal with Juiceworks Exhibits – a company that “creates brand experiences” for leading companies across North America with operations both in Canada and the USA.
PMED’s business objective: deploy artificial intelligence (AI) to disrupt impairment testing and healthcare.
Three weeks ago, Predictmedix filed a Patent Application in the U.S. for its AI-driven rapid screening system for infectious diseases.
Last week, Predictmedix appointed Kapil Raval to be the Chairman of its Advisory Board. Kapil is currently a director at the $1.4 trillion Microsoft (MSFT.NASDAQ).
